131 related articles for article (PubMed ID: 37517292)
21. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
[TBL] [Abstract][Full Text] [Related]
22. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
23. Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway.
Yu J; Wang X; Lu Q; Wang J; Li L; Liao X; Zhu W; Lv L; Zhi X; Yu J; Jin Y; Zou Q; Ou Z; Liu X; Zhou P
Int J Cancer; 2018 Mar; 142(5):959-967. PubMed ID: 29047106
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
de Leve S; Wirsdörfer F; Jendrossek V
Front Immunol; 2019; 10():698. PubMed ID: 31024543
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
[TBL] [Abstract][Full Text] [Related]
26. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
[TBL] [Abstract][Full Text] [Related]
27. Extracellular adenosine produced by ecto-5'-nucleotidase (CD73) regulates macrophage pro-inflammatory responses, nitric oxide production, and favors Salmonella persistence.
Costales MG; Alam MS; Cavanaugh C; Williams KM
Nitric Oxide; 2018 Jan; 72():7-15. PubMed ID: 29108754
[TBL] [Abstract][Full Text] [Related]
28. Detection of CD39 and a Highly Glycosylated Isoform of Soluble CD73 in the Plasma of Patients with Cervical Cancer: Correlation with Disease Progression.
Muñóz-Godínez R; de Lourdes Mora-García M; Weiss-Steider B; Montesinos-Montesinos JJ; Del Carmen Aguilar-Lemarroy A; García-Rocha R; Hernández-Montes J; Azucena Don-López C; Ávila-Ibarra LR; Torres-Pineda DB; Molina-Castillo G; Chacón-Salinas R; Vallejo-Castillo L; Pérez-Tapia SM; Monroy-García A
Mediators Inflamm; 2020; 2020():1678780. PubMed ID: 33488292
[TBL] [Abstract][Full Text] [Related]
29. Myeloid Cell-Derived TGFβ Signaling Regulates ECM Deposition in Mammary Carcinoma via Adenosine-Dependent Mechanisms.
Vasiukov G; Novitskaya T; Zijlstra A; Owens P; Ye F; Zhao Z; Moses HL; Blackwell T; Feoktistov I; Novitskiy SV
Cancer Res; 2020 Jun; 80(12):2628-2638. PubMed ID: 32312837
[TBL] [Abstract][Full Text] [Related]
30. Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.
Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Iser IC; Lenz GS; de Oliveira FH; Venturin G; Greggio S; daCosta JC; Wink MR; Sevigny J; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
Mol Neurobiol; 2020 Feb; 57(2):635-649. PubMed ID: 31407144
[TBL] [Abstract][Full Text] [Related]
31. CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy.
Chen S; Fan J; Zhang M; Qin L; Dominguez D; Long A; Wang G; Ma R; Li H; Zhang Y; Fang D; Sosman J; Zhang B
Nat Commun; 2019 Jan; 10(1):150. PubMed ID: 30635578
[TBL] [Abstract][Full Text] [Related]
32. Enzyme activity of circulating CD73 in human serum.
Morello S; Turiello R; Madonna G; Pinto A; Ascierto PA; Capone M
Methods Enzymol; 2019; 629():257-267. PubMed ID: 31727244
[TBL] [Abstract][Full Text] [Related]
33. Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A
Carmo M; Gonçalves FQ; Canas PM; Oses JP; Fernandes FD; Duarte FV; Palmeira CM; Tomé AR; Agostinho P; Andrade GM; Cunha RA
Br J Pharmacol; 2019 Sep; 176(18):3666-3680. PubMed ID: 31220343
[TBL] [Abstract][Full Text] [Related]
34. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
35. An IL6-Adenosine Positive Feedback Loop between CD73
Hu G; Cheng P; Pan J; Wang S; Ding Q; Jiang Z; Cheng L; Shao X; Huang L; Huang J
Cancer Immunol Res; 2020 Oct; 8(10):1273-1286. PubMed ID: 32847938
[TBL] [Abstract][Full Text] [Related]
36. An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach.
Arab S; Hasannejad F
Clin Transl Oncol; 2022 May; 24(5):742-756. PubMed ID: 34792724
[TBL] [Abstract][Full Text] [Related]
37. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
38. CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A
Yan A; Joachims ML; Thompson LF; Miller AD; Canoll PD; Bynoe MS
J Neurosci; 2019 May; 39(22):4387-4402. PubMed ID: 30926752
[TBL] [Abstract][Full Text] [Related]
39. A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation.
Morandi F; Morandi B; Horenstein AL; Chillemi A; Quarona V; Zaccarello G; Carrega P; Ferlazzo G; Mingari MC; Moretta L; Pistoia V; Malavasi F
Oncotarget; 2015 Sep; 6(28):25602-18. PubMed ID: 26329660
[TBL] [Abstract][Full Text] [Related]
40. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
